{"id":"gnrha-with-tamoxifen","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal bleeding/spotting"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Endometrial thickening"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gonadotropin-releasing hormone agonists (GnRHa) downregulate the hypothalamic-pituitary-gonadal axis, reducing ovarian estrogen synthesis in premenopausal women. Tamoxifen acts as a selective estrogen receptor modulator (SERM), competitively blocking estrogen binding to its receptor on breast cancer cells. The combination provides complementary hormonal suppression and receptor antagonism.","oneSentence":"GnRHa suppresses estrogen production while tamoxifen blocks estrogen receptor signaling, providing dual hormonal inhibition for hormone-sensitive breast cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:11.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer in premenopausal women"}]},"trialDetails":[{"nctId":"NCT01712893","phase":"PHASE3","title":"Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2009-06","conditions":"Breast Cancer","enrollment":216},{"nctId":"NCT01622361","phase":"PHASE3","title":"Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2012-06","conditions":"Breast Cancer","enrollment":290}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Endocrine Therapy"],"phase":"phase_3","status":"active","brandName":"GnRHa with Tamoxifen","genericName":"GnRHa with Tamoxifen","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GnRHa suppresses estrogen production while tamoxifen blocks estrogen receptor signaling, providing dual hormonal inhibition for hormone-sensitive breast cancer. Used for Hormone receptor-positive breast cancer in premenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}